MetaCap

NanoViricides (NNVC) vs Rein Therapeutics (RNTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NanoViricides (NNVC) has outperformed Rein Therapeutics (RNTX) over the past year, losing 10.2% versus a loss of 77.2%. Over five years, NNVC leads with a -76.5% price change compared with -97.5% for RNTX. NanoViricides is the larger company by market cap ($29.1 million vs $29.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NNVC-10.24%RNTX-77.24%
+53%-15%-83%
Nov 21, 20251 yearNov 20, 2026
NNVC-75.16%RNTX-97.57%
+11%-46%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NNVC versus RNTX key metrics
MetricNNVCRNTX
Share price$1.14$0.3369
Market cap$29.13M$29.06M
1-day change-2.56%-8.38%
YTD return+0.88%-70.96%
1-year return-10.24%-77.24%
5-year return-76.54%-97.47%
EPS (TTM)$-0.53$-1.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$0
Net income (latest FY)$-8.22M$-49.87M
52-week high$1.93$2.10
52-week low$0.85$0.284
Distance from 52-week high-40.93%-83.96%
Analyst consensusstrong_buynone
Avg. price target upside+426.32%+1680.94%
Average volume356.86K586.68K
Shares outstanding25.55M86.27M
Employees710
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NNVC has outperformed RNTX by 67.0 percentage points over the past year.

About NanoViricides

NNVC stock →

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Rein Therapeutics

RNTX stock →

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

NNVC vs RNTX FAQ

Which is bigger, NanoViricides or Rein Therapeutics?

NanoViricides (NNVC) is larger, with a market capitalization of $29.13M compared with $29.06M for Rein Therapeutics (RNTX).

Which stock has performed better over the past year, NNVC or RNTX?

NNVC returned -10.24% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.

Are NanoViricides and Rein Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons